ReShape Lifesciences Inc Net Assets
ReShape Lifesciences Inc net assets. Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) has net assets worth $5.83 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.03 Million) and total liabilities ($3.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore RSLS net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.83 Million |
| % of Total Assets | 64.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | -101.75% |
| 10-Year Change | -106.89% |
| Growth Volatility | 627.91 |
Net Assets of ReShape Lifesciences Inc (2003–2024)
Net assets of ReShape Lifesciences Inc from 2003 to 2024. This chart illustrates how ReShape Lifesciences Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of ReShape Lifesciences Inc to measure how much of total assets are equity-financed.
Annual Net Assets for ReShape Lifesciences Inc (2003–2024)
The table below shows the annual net assets of ReShape Lifesciences Inc from 2003 to 2024. For live market cap and overall valuation, see RSLS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-253.00K | -103.80% |
| 2023-12-31 | $6.66 Million | +82.00% |
| 2022-12-31 | $3.66 Million | -92.05% |
| 2021-12-31 | $46.07 Million | +218.00% |
| 2020-12-31 | $14.49 Million | -39.90% |
| 2019-12-31 | $24.11 Million | -23.87% |
| 2018-12-31 | $31.66 Million | -58.54% |
| 2017-12-31 | $76.37 Million | +2498.40% |
| 2016-12-31 | $2.94 Million | -19.98% |
| 2015-12-31 | $3.67 Million | -44.88% |
| 2014-12-31 | $6.66 Million | -54.60% |
| 2013-12-31 | $14.68 Million | +23.61% |
| 2012-12-31 | $11.88 Million | -40.75% |
| 2011-12-31 | $20.04 Million | -32.54% |
| 2010-12-31 | $29.71 Million | +432.29% |
| 2009-12-31 | $5.58 Million | -51.07% |
| 2008-12-31 | $11.41 Million | -74.81% |
| 2007-12-31 | $45.28 Million | +58.47% |
| 2006-12-31 | $28.57 Million | +1347.10% |
| 2005-12-31 | $1.97 Million | +394.71% |
| 2003-12-31 | $-670.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ReShape Lifesciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64020000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ReShape Lifesciences Inc Net Assets Breakdown (December 2024)
ReShape Lifesciences Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00K | % |
| Other Comprehensive Income | $-104.00K | % |
| Other Components | $642.53 Million | % |
| Total Equity | $-253.00K | 100.00% |
ReShape Lifesciences Inc Competitors by Market Cap
The table below lists competitors of ReShape Lifesciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eastern International Ltd.
NASDAQ:ELOG
|
$9.35 Million |
|
Kodi-M Co Ltd
KQ:224060
|
$9.36 Million |
|
Praxis Home Retail Limited
NSE:PRAXIS
|
$9.36 Million |
|
In8bio Inc
NASDAQ:INAB
|
$9.36 Million |
|
TEN Holdings, Inc. Common Stock
NASDAQ:XHLD
|
$9.35 Million |
|
Pergamon Status Dis Ticaret AS
IS:PSDTC
|
$9.35 Million |
|
TAO Synergies Inc.
NASDAQ:TAOX
|
$9.35 Million |
|
Hengli Industrial Development Group Co Ltd
SHE:000622
|
$9.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ReShape Lifesciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,663,000 to -253,000, a change of -6,916,000 (-103.8%).
- Net loss of 7,130,000 reduced equity.
- Other comprehensive income decreased equity by 16,000.
- Other factors increased equity by 230,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.13 Million | -2818.18% |
| Other Comprehensive Income | $-16.00K | -6.32% |
| Other Changes | $230.00K | +90.91% |
| Total Change | $- | -103.80% |
Book Value vs Market Value Analysis
This analysis compares ReShape Lifesciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $-12219.59 | $3.92 | x |
| 2005-12-31 | $14716.79 | $3.92 | x |
| 2006-12-31 | $160139.95 | $3.92 | x |
| 2007-12-31 | $53708.36 | $3.92 | x |
| 2008-12-31 | $1964.58 | $3.92 | x |
| 2009-12-31 | $3253.70 | $3.92 | x |
| 2010-12-31 | $10232.18 | $3.92 | x |
| 2011-12-31 | $1924.11 | $3.92 | x |
| 2012-12-31 | $871.03 | $3.92 | x |
| 2013-12-31 | $13.34 | $3.92 | x |
| 2014-12-31 | $867708.33 | $3.92 | x |
| 2015-12-31 | $329.86 | $3.92 | x |
| 2016-12-31 | $60560.48 | $3.92 | x |
| 2017-12-31 | $9930689.21 | $3.92 | x |
| 2018-12-31 | $2494.87 | $3.92 | x |
| 2019-12-31 | $768.25 | $3.92 | x |
| 2020-12-31 | $556.57 | $3.92 | x |
| 2021-12-31 | $294187.13 | $3.92 | x |
| 2022-12-31 | $12508.54 | $3.92 | x |
| 2023-12-31 | $1622.35 | $3.92 | x |
| 2024-12-31 | $-12.27 | $3.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ReShape Lifesciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -89.06%
- • Asset Turnover: 1.67x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-303.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.83 Million |
| 2005 | -567.99% | 0.00% | 0.00x | 5.85x | $-11.41 Million |
| 2006 | -61.91% | 0.00% | 0.00x | 1.26x | $-20.55 Million |
| 2007 | -63.11% | 0.00% | 0.00x | 1.30x | $-33.10 Million |
| 2008 | -332.08% | 0.00% | 0.00x | 2.48x | $-39.01 Million |
| 2009 | -572.10% | 0.00% | 0.00x | 2.91x | $-32.49 Million |
| 2010 | -58.39% | 0.00% | 0.00x | 1.30x | $-20.32 Million |
| 2011 | -129.72% | 0.00% | 0.00x | 1.62x | $-28.00 Million |
| 2012 | -197.56% | -7519.23% | 0.01x | 2.20x | $-24.65 Million |
| 2013 | -175.63% | -8276.59% | 0.01x | 1.80x | $-27.25 Million |
| 2014 | -392.09% | 0.00% | 0.00x | 2.16x | $-26.80 Million |
| 2015 | -694.23% | -8732.53% | 0.03x | 3.15x | $-25.87 Million |
| 2016 | -794.86% | -2969.62% | 0.11x | 2.40x | $-23.65 Million |
| 2017 | -44.28% | -2627.34% | 0.01x | 1.16x | $-41.45 Million |
| 2018 | -256.30% | -13375.68% | 0.01x | 1.46x | $-84.32 Million |
| 2019 | -307.84% | -491.80% | 0.38x | 1.65x | $-76.62 Million |
| 2020 | -149.30% | -191.43% | 0.30x | 2.56x | $-23.08 Million |
| 2021 | -139.70% | -455.39% | 0.25x | 1.22x | $-66.37 Million |
| 2022 | -1262.33% | -411.16% | 1.01x | 3.04x | $-46.58 Million |
| 2023 | -170.90% | -131.22% | 0.81x | 1.60x | $-12.05 Million |
| 2024 | 0.00% | -89.06% | 1.67x | 0.00x | $-7.10 Million |
Industry Comparison
This section compares ReShape Lifesciences Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ReShape Lifesciences Inc (RSLS) | $5.83 Million | 0.00% | 0.55x | $9.35 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more